

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

GEN2.2

RRID:CVCL_5G44

Type: Cell Line

Proper Citation

RRID:CVCL_5G44

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_5G44

Proper Citation: RRID:CVCL_5G44

Description: Cell line GEN2.2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Blastic plasmacytoid dendritic cell neoplasm

Defining Citation: [PMID:16365416](#), [PMID:22696054](#)

Comments: Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: GEN2.2

Synonyms: Gen2.2, GEN 2.2, Gen 2.2, HLA-A*0201+ pDC line

Cross References: Wikidata:Q54835560

ID: CVCL_5G44

Record Creation Time: 20220427T215859+0000

Record Last Update: 20260905T175351+0000

Ratings and Alerts

No rating or validation information has been found for GEN2.2.

No alerts have been found for GEN2.2.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Mekkaoui Z, et al. (2026) Metformin dual-targets metabolism and survival pathways in BPDCN. iScience, 29(7), 116323.

Fredon M, et al. (2024) Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells. Cancer immunology research, 12(8), 1090.

Morell M, et al. (2022) SIDT1 plays a key role in type I IFN responses to nucleic acids in plasmacytoid dendritic cells and mediates the pathogenesis of an imiquimod-induced psoriasis model. EBioMedicine, 76, 103808.